Metabolic conditions — including insulin resistance, excess visceral fat, and impaired blood sugar regulation — are among the most prevalent chronic health challenges today. Researchers have been exploring whether compounds produced by the gut microbiome from dietary polyphenols might support metabolic function at the cellular level. Urolithin A has emerged as one of the more closely studied candidates in this space.
Urolithin A is not consumed directly from food. Your gut bacteria produce it when you eat ellagitannins — polyphenols found in pomegranates, walnuts, and certain berries. However, production varies significantly between individuals depending on gut microbiome composition. Because of this variability, researchers have studied both dietary sources of ellagitannins and supplemental urolithin A to understand its potential metabolic effects.
Key Takeaways
- Urolithin A is produced by gut bacteria from ellagitannins in foods like pomegranates and walnuts; production varies widely between individuals based on microbiome composition.
- The primary proposed mechanism for metabolic benefits is activation of mitophagy — the cellular process that clears damaged mitochondria and supports efficient energy metabolism.
- Preclinical research suggests urolithin A may improve insulin sensitivity and glucose uptake in skeletal muscle, reduce obesity-related metabolic dysfunction, and protect against metabolic cardiomyopathy in animal models.
- Most evidence comes from cell culture and animal studies; large-scale human clinical trials specifically testing urolithin A for metabolic outcomes remain limited.
- Polyphenol-rich dietary patterns, including those featuring pomegranate, are associated with reduced visceral fat and improved metabolic aging markers in human randomized trial data.
How Urolithin A Is Produced and Why Variability Matters
Urolithin A belongs to a class of compounds called postbiotics — bioactive molecules generated by gut bacteria from dietary precursors. Ellagitannins, found in pomegranates, walnuts, raspberries, and strawberries, are broken down into ellagic acid in the gut, which certain bacteria then convert into urolithin A [12]. The key word is ‘certain’: not everyone harbors the bacterial strains required for meaningful urolithin A production, meaning two people eating identical diets can have very different circulating levels.
This variability has important implications for interpreting the research. Studies using supplemental urolithin A bypass the gut-conversion step and deliver the compound directly, which may explain why supplementation trials sometimes show clearer results than dietary-polyphenol interventions. A 2021 review of urolithin A’s role in metabolic diseases highlights this interindividual variation as a central factor in understanding who might benefit most from dietary sources versus supplementation [3].
Mitophagy and Mitochondrial Renewal: The Core Proposed Mechanism
Much of the interest in urolithin A for metabolic health centers on its apparent ability to activate mitophagy — the cellular process by which damaged or dysfunctional mitochondria are identified and cleared. Mitochondria are the organelles responsible for converting nutrients into usable energy, and their quality declines with age and in the context of metabolic stress. When damaged mitochondria accumulate, cellular energy production becomes less efficient, which is thought to contribute to insulin resistance and related dysfunction.
Research in mice and human cell models suggests urolithin A can stimulate this mitochondrial housekeeping process, leading to a net improvement in mitochondrial quality and the growth of new mitochondria — a process called biogenesis [1]. In human skeletal muscle cells specifically, urolithin A has been shown to augment glucose uptake, an effect the researchers associated with improved mitochondrial function [10]. Skeletal muscle is a major site of glucose disposal in the body, so improvements there can meaningfully affect whole-body blood sugar regulation.
Insulin Sensitivity and Blood Sugar Regulation
Several preclinical studies have examined urolithin A’s effects on insulin sensitivity directly. In a study using obese mouse models, urolithin A improved insulin sensitivity, with the authors attributing this to augmented mitochondrial function and biogenesis in skeletal muscle [1]. A separate study found that both ellagic acid and urolithin A could alleviate diet-induced insulin resistance in mice, suggesting beneficial effects are present across related compounds in this metabolic pathway [2].
Research using cultured L6 myotubes — a standard skeletal muscle cell model — and a type 2 diabetic mouse strain with glucose intolerance found that urolithin A demonstrated antidiabetic effects in both systems [8]. A 2025 study in human skeletal muscle cells found urolithin A not only augmented glucose uptake but also suppressed myostatin expression, a protein that normally limits muscle growth, suggesting potential dual benefits for muscle function and metabolic health [10].
It is important to note that the majority of this research is preclinical, meaning it was conducted in cell cultures or animal models. A 2025 review examining urolithin A in the context of insulin resistance notes that human clinical trial data specifically testing these outcomes is limited, and results from animal models do not always translate directly to people [11].
Obesity and Adiposity: Emerging Preclinical Evidence
Urolithin A has been described as a multi-target candidate for obesity and metabolic dysfunction, with proposed mechanisms spanning mitophagy activation, anti-inflammatory effects, and modulation of fat cell development [12]. A review specifically examining urolithin A’s immunomodulatory role in metabolic diseases noted that low-grade chronic inflammation is a key driver of metabolic dysfunction in obesity, and that urolithin A appears to modulate several inflammatory pathways relevant to this process [3].
A systematic review of postbiotics — the broader compound class to which urolithin A belongs — for anti-obesity effects found preliminary evidence across both preclinical and clinical studies that these compounds can influence body weight, fat mass, and metabolic markers, though the authors noted that human trial evidence remains limited in scale and duration [9]. For urolithin A specifically, the anti-obesity evidence base is still largely preclinical, and no large-scale human randomized controlled trials on body weight have been published to date.
Metabolic Cardiomyopathy: Protecting the Heart from Metabolic Stress
Metabolic dysfunction — particularly obesity and poorly controlled diabetes — can impair heart muscle function over time, a condition called metabolic cardiomyopathy. Researchers have investigated whether urolithin A’s mitophagy-activating properties might offer protection in this context. A mouse study found that urolithin A ameliorated obesity-induced metabolic cardiomyopathy, with the authors attributing this to mitophagy activation in cardiac tissue — clearing damaged mitochondria from heart muscle cells to restore more normal function [5].
In a separate study using a rat model of diabetic cardiomyopathy, urolithin A treatment was associated with cardiac protection through activation of SIRT1, a protein involved in cellular stress responses and mitochondrial regulation [4]. Both studies were conducted in animal models, which means applicability to human cardiac disease is not yet established. They do, however, point to a mechanistic pathway that researchers are continuing to examine.
Polyphenol-Rich Diets and Metabolic Aging: Broader Context
While direct human evidence on urolithin A supplementation specifically for metabolic outcomes is still accumulating, research on polyphenol-rich dietary patterns offers relevant context. The DIRECT PLUS randomized controlled trial found that a high-polyphenol Mediterranean diet led to reductions in visceral adiposity — deep abdominal fat associated with metabolic risk — compared to a standard Mediterranean diet [6]. A subsequent analysis from the same trial found that polyphenol-rich eating was associated with attenuation of biological age as measured by DNA methylation markers [7].
These findings do not isolate urolithin A specifically, since polyphenol-rich diets contain many bioactive compounds. However, pomegranate — one of the richest dietary sources of ellagitannins that yield urolithin A — was among the dietary components studied. This situates urolithin A research within a broader evidence base supporting polyphenol-rich eating for metabolic and aging-related outcomes.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10) — established clinical-supplement brand, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The majority of evidence on urolithin A and metabolic health comes from cell culture and animal studies; human clinical trials are limited in number and scale, and findings from animal models do not reliably predict effects in people. Urolithin A is not a substitute for established treatments for insulin resistance, obesity, type 2 diabetes, or cardiovascular disease — if you have any of these conditions or take medications affecting blood sugar, consult your doctor before adding any supplement.
Frequently Asked Questions
What metabolic conditions has urolithin A been studied for?
Urolithin A has been studied primarily in preclinical models of insulin resistance, type 2 diabetes, obesity-related metabolic dysfunction, and metabolic cardiomyopathy [12] [3]. Human clinical evidence is still limited in scope, and these findings should not be interpreted as proof of effectiveness in people with diagnosed metabolic conditions.
How does urolithin A affect insulin sensitivity?
Research in obese mouse models found that urolithin A improved insulin sensitivity through augmentation of mitochondrial function and biogenesis in skeletal muscle [1]. A study in human skeletal muscle cells showed urolithin A augmented glucose uptake and suppressed myostatin, pointing to a possible mechanism for improving how muscle tissue handles blood sugar [10].
Can urolithin A help with weight management or obesity?
Urolithin A has been proposed as a multi-target candidate for obesity based on its effects on mitophagy, inflammation, and fat metabolism in preclinical research [12]. A systematic review of postbiotics found preliminary evidence for anti-obesity effects, but large-scale human trial data for urolithin A specifically is not yet available [9]. It should not be considered a weight loss treatment at this time.
Is there evidence for urolithin A protecting the heart in the context of metabolic disease?
Animal studies have found urolithin A may protect against obesity-induced and diabetes-induced cardiomyopathy through mitophagy activation and SIRT1 signaling in cardiac tissue [5] [4]. These findings have not yet been replicated in human cardiac studies, so conclusions about heart protection in people cannot be drawn.
Do I need a supplement to benefit, or can food sources provide enough urolithin A?
Your gut bacteria produce urolithin A from ellagitannins in foods like pomegranates, walnuts, and berries, but not everyone’s microbiome makes meaningful amounts [12]. High-polyphenol diets including these foods have demonstrated metabolic benefits in human randomized trials independent of urolithin A isolation [6]. Whether food alone provides sufficient urolithin A for the effects seen in preclinical studies is not yet established.
Why does gut microbiome composition matter so much for urolithin A?
Only specific gut bacterial species can convert ellagic acid into urolithin A, and the population of these bacteria differs substantially between people [3]. This explains why two individuals eating identical pomegranate-rich diets may have very different urolithin A blood levels, and why supplemental forms that deliver urolithin A directly have become an active area of research alongside dietary approaches [12].
References
- Toney AM et al. Urolithin A, a Gut Metabolite, Improves Insulin Sensitivity Through Augmentation of Mitochondrial Function and Biogenesis. Obesity (Silver Spring, Md.) (2019). PMID 30768775
- Yang J et al. Ellagic Acid and Its Microbial Metabolite Urolithin A Alleviate Diet-Induced Insulin Resistance in Mice. Molecular nutrition & food research (2020). PMID 32783299
- Toney AM et al. Immunomodulatory Role of Urolithin A on Metabolic Diseases. Biomedicines (2021). PMID 33671880
- Albasher G et al. Urolithin A prevents streptozotocin-induced diabetic cardiomyopathy in rats by activating SIRT1. Saudi journal of biological sciences (2022). PMID 35241966
- Huang JR et al. Urolithin A ameliorates obesity-induced metabolic cardiomyopathy in mice via mitophagy activation. Acta pharmacologica Sinica (2023). PMID 35655094
- Zelicha H et al. The effect of high-polyphenol Mediterranean diet on visceral adiposity: the DIRECT PLUS randomized controlled trial. BMC medicine (2022). PMID 36175997
- Yaskolka Meir A et al. The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT PLUS randomized controlled trial. BMC medicine (2023). PMID 37743489
- Kondo S et al. Antidiabetic Effect of Urolithin A in Cultured L6 Myotubes and Type 2 Diabetic Model KK-A(y)/Ta Mice with Glucose Intolerance. Current issues in molecular biology (2024). PMID 38392186
- Eslami M et al. The anti-obesity effects of postbiotics: A systematic review of pre-clinical and clinical studies. Clinical nutrition ESPEN (2024). PMID 39461594
- Wilhelmsen A et al. The polyphenol metabolite urolithin A suppresses myostatin expression and augments glucose uptake in human skeletal muscle cells. Nutrition & metabolism (2025). PMID 39962542
- Joseph V et al. Microbial Metabolite, Macro Impact: Urolithin A in the Nexus of Insulin Resistance and Colorectal Tumorigenesis. Nutrients (2025). PMID 41374004
- Liu C et al. Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction. Frontiers in endocrinology (2026). PMID 41884209
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
